Orchid Pharma Peer Comparison

NSE: ORCHPHARMA | BSE: 524372

₹902.15

₹25.40 (2.90%)

As on 05-Nov-2026IST

Market cap

₹5,413 Cr

Revenue (TTM)

₹943 Cr

P/E Ratio

624.6

P/B Ratio

3.5

Div. Yield

0 %

Edit

	Orchid Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	5,413	42,850	25,088	18,357	14,047
Revenue (₹ Cr)	943	10,234	2,307	2,684	1,170
Net Profit (₹ Cr)	9.88	1,092.67	452.55	669.74	279.64
Net Margin (%)	1.02	10.67	19.31	24.24	22.94
RoE (%)	1.21	21.65	23.18	19.79	13.92
Price to Earnings	624.59	39.19	55.44	27.41	49.73
Price-To-Book	3.45	8.02	12.37	5.06	6.73

Income Statement (₹ Cr)

	Orchid Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	942.57	10,234.10	2,307.19	2,684.41	1,170.41
Total Income	968.12	10,245.27	2,343.69	2,763.43	1,218.73
Total Expenditure	901.62	8,141.47	1,602.28	1,761.70	766.14
EBITDA	40.95	2,092.63	704.92	922.70	404.27
Depreciation	37.75	430.12	104.34	82.27	74.77
EBIT	3.21	1,662.51	600.57	840.44	329.50
Interest	12.23	151.49	28.27	5.42	0.24
Other Income	25.55	11.17	36.50	79.02	48.32
Exceptional Items	-6.57	-27.85	0.00	-25.66	-3.28
Profit before Tax	9.96	1,494.35	608.80	888.39	374.31
Provision for Tax	0.07	401.68	156.25	218.65	94.68
Profit after Tax	9.88	1,092.67	452.55	669.74	279.64

	Orchid Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	1,287.79	5,344.04	2,029.71	3,631.29	2,075.76
Minority Interest	0.00	0.82	0.00	0.00	3.07
Non-Current Liabilities	344.16	980.81	381.27	146.95	53.38
Current Liabilities	278.97	3,838.93	618.58	563.70	201.71
Total Liabilities	2,258.43	9,514.48	2,930.14	4,157.10	2,231.79

	Orchid Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	1,080.13	3,542.74	1,471.67	1,454.42	980.16
Current Assets	683.90	6,027.59	1,389.85	2,864.85	1,290.68
Total Assets	2,258.43	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	301.44	1,204.08	196.61	0.00	0.00
Net Current Assets	404.93	2,188.66	771.28	2,301.15	1,088.97
Contingent Liabilities	24.51	258.92	13.18	4.82	3.76

	Orchid Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	125.64	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-276.88	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	137.14	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	-14.10	93.92	-56.08	-69.08	11.28

	Orchid Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	1.11	25.25	27.50	24.61	18.04
ROE (%)	1.21	21.65	23.18	19.79	13.92
ROA (%)	0.55	11.17	16.27	16.78	12.86
EBIT Margin (%)	0.34	16.24	26.03	31.31	28.15
Net Margin (%)	1.02	10.67	19.31	24.24	22.94
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Orchid Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	0.20	21.12	50.46	8.19	4.02
EBIT Growth (%)	-92.44	32.84	138.53	24.77	-11.95
Net Profit Growth (%)	-83.69	33.33	88.45	26.27	-12.44
EPS Growth (%)	-76.03	38.63	131.13	29.79	-12.06
Book Value Growth (%)	0.69	11.36	22.95	18.43	11.27

	Orchid Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	287.33	37.01	55.61	27.09	24.06
Price / Book Value	3.35	7.72	12.40	5.15	3.30
Dividend Yield (%)	0.00	0.17	0.17	0.33	0.58
EV/EBITDA	133.64	20.22	35.47	19.42	32.88
Market Cap (₹ Cr)	731.78	30,257.56	15,412.11	11,956.86	10,627.92

	Orchid Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	0.25	0.10	0.10	0.00	0.00
Short term debt to equity ratio	0.06	0.16	--	--	--
Current Ratio	2.45	1.57	2.25	5.08	6.40
Quick Ratio	1.53	0.92	1.35	3.69	4.43
Interest Coverage	1.81	10.86	22.53	165.03	1,593.82

	Orchid Pharma	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	27.99	26.69	12.76	36.81	35.24
Asset Turnover	0.52	1.05	0.83	0.67	0.54
Receivable days	108.72	88.68	77.32	144.58	169.86
Inventory Days	122.82	84.11	80.83	96.67	97.92
Payable days	147.58	176.65	125.94	135.45	159.68
Cash Conversion Cycle	83.97	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.